Senior Scientist
AstraZeneca
Disclosure(s): AstraZeneca: Employee of AstraZeneca and may own AstraZeneca stock or stock options.
Kevin joined AstraZeneca in 2017, and is now a Senior Scientist within the Translational Medicine group as part of the AstraZeneca Vaccines and Immune Therapies unit. Kevin currently leads a team that focuses on the monitoring of phenotypic resistance of viral variants, including SARS-CoV-2, through clinical exploratory and surveillance endpoints. Kevin received his MS in Biomedical Sciences from Pennsylvania State University in 2016 while studying the potential nuclear function of human immunodeficiency virus type 1 Gag protein.